Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055429 | 0.93 | TERT (0.56) | TERTNPC1RAB9ABRD4MEN1 | |
| SCHEMBL30357138 | 0.93 | TERT (0.65) | TERTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1792 | 0.93 | TERT (0.65) | TERTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL8067045 | 0.90 | TERT (0.52) | TERTBRD4MEN1KMT2ALMNA | |
| SCHEMBL1443 | 0.88 | TERT (0.60) | TERTNPC1RAB9ALMNAMAPT | |
| SCHEMBL13662765 | 0.87 | TERT (0.48) | TERTBRD4MEN1KMT2ALMNA | |
| SCHEMBL3670031 | 0.87 | TERT (0.63) | TERTNPC1RAB9ALMNAMAPT | |
| SCHEMBL7003270 | 0.85 | TERT (0.48) | TERTBRD4MEN1KMT2ALMNA | |
| SCHEMBL8065704 | 0.84 | TERT (0.46) | TERTBRD4MEN1KMT2ALMNA | |
| SCHEMBL1705329 | 0.83 | TERT (0.61) | TERTNPC1RAB9ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107759603-B | Preparation method of heterocyclic compound | 四川科伦药物研究院有限公司 | 2020-09-01 | — | — | CN | disclosed |
| US-8796286-B2 | Agent for treatment of liver diseases containing pyrazolopyrimidinone derivative | MEZZION PHARMA CO., LTD. (KR) | 2014-08-05 | — | — | US | disclosed |
| EP-2167093-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND | DONG A PHARM CO LTD (KR) | 2012-04-18 | — | — | EP | disclosed |
| US-8148386-B2 | Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound | DONG-A PHARMTECH CO., LTD. (KR) | 2012-04-03 | — | — | US | disclosed |
| US-20110306762-A1 | ACID ADDITION SALT OF UDENAFIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
| US-20100210668-A1 | COMPOSITION AND METHOD FOR TREATMENT OR PREVENTION OF BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS | DONG-A PHARM. CO., LTD. (KR) | 2010-08-19 | — | — | US | disclosed |
| US-20100173915-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2010-07-08 | — | — | US | disclosed |
| EP-2192903-A2 | COMPOSITION AND METHOD FOR TREATMENT OR PREVENTION OF BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS | Dong-A Pharm.Co., Ltd. (KR) | 2010-06-09 | — | — | EP | disclosed |
| EP-2167093-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND | Dong-A Pharmaceutical Co., Ltd. (KR) | 2010-03-31 | — | — | EP | disclosed |
| US-20090099357-A1 | AGENT FOR THE PREVENTION AND TREATMENT OF PROSTATIC HYPERPLASIA COMPRISING PYRAZOLOPYRIMIDINONE COMPOUND | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2009-04-16 | — | — | US | disclosed |
| US-6200980-B1 | ADMINISTERING PHENYL PURINONE COMPOUND FOR TREATING PRECANCEROUS LEISONS | CELL PATHWAYS, INC. | 2001-03-13 | — | — | US | disclosed |
| US-5719283-A | INHIBITORS OF PHOSPHODIESTERASES; CARDIOVASCULAR DISORDERS | PFIZER INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0526004-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1997-10-08 | — | — | EP | disclosed |
| US-5426107-A | Treatment of cardiovascular disorders, asthma, allergies | PFIZER INC. (US) | 1995-06-20 | — | — | US | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5272147-A | Pyrazolopyrimidinone antianginal agents | PFIZER INC. (US) | 1993-12-21 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306762-A1 | ACID ADDITION SALT OF UDENAFIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACSS2, ADSL, OTC | TERT 4271/4885NPC1 2681/4885RAB9A 4057/4885 |
| US-20090099357-A1 | AGENT FOR THE PREVENTION AND TREATMENT OF PROSTATIC HYPERPLASIA COMPRISING PYRAZOLOPYRIMIDINONE COMPOUND | PDE5A, PDE3A, PDE3B | TERT 2378/4885NPC1 4018/4885RAB9A 2324/4885 |
| US-20100173915-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND | PDE3B, PDE5A, PDE3A | TERT 1512/4885NPC1 2063/4885RAB9A 1688/4885 |
| US-20100210668-A1 | COMPOSITION AND METHOD FOR TREATMENT OR PREVENTION OF BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS | BPHL, KLK3, KLK5 | TERT 2661/4885NPC1 2710/4885RAB9A 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.